15 records – page 1 of 1.

CMA's Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125
Date
2014-03-26
Topics
Pharmaceuticals, prescribing, cannabis, drugs
and abuse of prescription medication The use of prescription opioid pain relievers is on the rise, in Canada and internationally. Latest reports indicate that Canada has the second highest per capita consumption of prescription opioids in the world, after the United States. The misuse and abuse

CMA submission to the study of Bill C-37

https://policybase.cma.ca/link/policy13617
Date
2017-04-06
Topics
Pharmaceuticals, prescribing, cannabis, drugs

Consultation on the prescription drug list: Naloxone

https://policybase.cma.ca/link/policy11847
Date
2016-03-19
Topics
Pharmaceuticals, prescribing, cannabis, drugs
”. The CMA has over 83,000 physician-members. Its mission is helping physicians care for patients and its vision is to be the leader in engaging and serving physicians, and the national voice for the highest standards for health and health care. The harms associated with opioids, which include

Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/link/policy11535
Date
2015-05-30
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Service Centre, Canadian Medical Association, 1867 Alta Vista Drive, Ottawa, ON K1G 5W8; tel 888 855-2555 or 613 731-8610 x2307; fax 613 236-8864. All polices of the CMA are available electronically through CMA Online (www.cma.ca). CMA POLICY HARMS ASSOCIATED WITH OPIOIDS AND OTHER

Health Canada consultation on Canadian drugs and substances strategy

https://policybase.cma.ca/link/policy14017
Date
2018-12-04
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Policy makers must recognize that prescription opioids are an essential tool in the alleviation of pain and suffering, particularly in palliative and cancer care.7 Doctors support patients in the management of acute and chronic pain, as well as problematic substance use, and as such have long been

Health Canada consultation on regulatory amendments regarding tramadol

https://policybase.cma.ca/link/policy13927
Date
2018-08-14
Topics
Pharmaceuticals, prescribing, cannabis, drugs
-risk in terms of addiction, it is nevertheless an opioid and should be placed in the Controlled Drugs and Substances Act, under Schedule 1.2 The Canadian Institute for Health Information reports that tramadol is one of six opioids accounting for 96% of all opioid prescriptions between 2012

Health Canada consultation on restriction of marketing and advertising of opioids

https://policybase.cma.ca/link/policy13921
Date
2018-07-18
Topics
Pharmaceuticals, prescribing, cannabis, drugs
CMA response: HEALTH CANADA CONSULTATION ON RESTRICTION OF MARKETING AND ADVERTISING OF OPIOIDS July 18, 2018 The Canadian Medical Association

The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035
Date
2013-11-27
Topics
Pharmaceuticals, prescribing, cannabis, drugs
for consideration as part of its study on the government’s role in addressing prescription drug abuse in Canada. It is increasingly recognized that while prescription medication has an important role in health care, the misuse and abuse of controlled psychoactive prescription medications, notably opioids

Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/link/policy13734
Date
2017-11-7
Topics
Pharmaceuticals, prescribing, cannabis, drugs
. Available: https://www.cma.ca/Assets/assets- library/document/en/advocacy/submissions/hesa-opioid-study-opening-remarks-oct-18-2016-e.pdf (accessed: 2017 Nov 7). 14 Canadian Medical Association. Harms Associated with Opioids and Other Psychoactive Prescription Drugs. CMA Policy, 2015. Ottawa

Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model

https://policybase.cma.ca/link/policy13932
Date
2018-10-31
Topics
Population health, health equity, public health

Proposed amendments to the marihuana for medical purposes regulations

https://policybase.cma.ca/link/policy11293
Date
2014-07-11
Topics
Pharmaceuticals, prescribing, cannabis, drugs
to patients and the possibility for misuse or abuse of medications, particularly opioids and other such substances. For these reasons, the CMA advocates for an inter-operable, pan-Canadian system of real-time prescription monitoring and surveillance for controlled substances. Robust monitoring

Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114
Date
2014-03-17
Topics
Pharmaceuticals, prescribing, cannabis, drugs
of controlled psychoactive prescription medicines, notably opioids such as oxycodone, fentanyl and hydrocodone, is a significant public health and patient safety issue. Canada has the second highest per capita consumption of prescription opioids in the world, after the United States. The abuse

Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada

https://policybase.cma.ca/link/policy13936
Date
2016-10-18
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety
crisis related to problematic opioid and fentanyl use. Physicians are on the front lines in many respects. Doctors are responsible for supporting patients with the management of acute and chronic pain. Policy makers must recognize that prescription opioids are an essential tool in the alleviation

Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

https://policybase.cma.ca/link/policy13931
Date
2018-08-30
Topics
Pharmaceuticals, prescribing, cannabis, drugs
and other necessary health services; and • benefit public order by reducing public injecting.3 As you know,Canada is experiencing a large-scale opioid overdose crisis. In Ontario alone, overdose deaths related to opioids increased by 45 per cent in 2017, with more than three people dying every day

Tamper Resistance under the Controlled Drugs and Substances Act

https://policybase.cma.ca/link/policy11295
Date
2014-08-26
Topics
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs
, there was a rise in the use of heroin and other opioids which did not have abuse deterrent technology 8, 9 . Tamper-resistant technologies have not been proven to be 100% effective in preventing abuse. They are not successful in preventing the most common form of abuse, which is the ingestion of a large

15 records – page 1 of 1.